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Abstract
Finnish gelsolin amyloidosis (AGel amyloidosis) is an autosomal dominantly inherited systemic disorder with
ophthalmologic, neurologic and dermatologic symptoms. Only the gelsolin (GSN) c.640G>A variant has been found in
the Finnish patients thus far. The purpose of this study was to examine whether the Finnish patients have a common ancestor
or whether multiple mutation events have occurred at c.640G, which is a known mutational hot spot. A total of 79 Finnish
AGel amyloidosis families including 707 patients were ﬁrst discovered by means of patient interviews, genealogic studies
and civil and parish registers. From each family 1-2 index patients were chosen. Blood samples were available from 71 index
patients representing 64 families. After quality control, SNP array genotype data were available from 68 patients from 62
nuclear families. All the index patients had the same c.640G>A variant (rs121909715). Genotyping was performed using the
Illumina CoreExome SNP array. The homozygosity haplotype method was used to analyse shared haplotypes. Haplotype
analysis identiﬁed a shared haplotype, common to all studied patients. This shared haplotype included 17 markers and
was 361 kb in length (GRCh37 coordinates 9:124003326–124364349) and this level of haplotype sharing was
found to occur highly unlikely by chance. This GSN haplotype ranked as the largest shared haplotype in the 68 patients
in a genome-wide analysis of haplotype block lengths. These results provide strong evidence that although there is a known
mutational hot spot at GSN c.640G, all of the studied 62 Finnish AGel amyloidosis families are genetically linked to a
common ancestor.
Introduction
Finnish type of hereditary gelsolin amyloidosis (AGel
amyloidosis) (OMIM (Online Mendelian Inheritance in
Man) #105120) or Meretoja’s disease is an autosomal
dominant systemic amyloidosis [1]. The number of patients
in Finland is estimated between 400 and 1000 [2, 3], which
makes it one of the most common diseases of the Finnish
disease heritage [4]. AGel amyloidosis has also been found
in many other European countries as well as in North
America [5–7], South America [8–10] and Asia [11, 12],
[13, 14]. The Finnish variant and most other ethnic variants
are caused by a mutation in the gelsolin (GSN) gene, located
on chromosome 9 at q33.2 [15], where guanine is replaced
by adenosine (NM_000177.4:c.640G>A, NP_000168.1:p.
Asp214Asn) [16, 17]. A less common variant in the same
locus c.640G>T has been reported to cause AGel amyloi-
dosis in Denmark, former Czechoslovakia, France, Brazil
[5], South Korea [14] and the United States [7]. In addition
to this, two recently identiﬁed GSN variants (c.633C>A and
c.580G>A) have been described to cause renal amyloidosis
in North America [18, 19].
The symptoms of AGel amyloidosis are thought to be a
consequence of generation and deposition of GSN amyloid
(AGel) ﬁbrils and pre-amyloid oligomers, which originate
from the misfolded variant GSN molecule and accumulate
in tissues [20]. These symptoms include particularly oph-
thalmologic, neurologic and dermatologic signs [5]. These
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signs are recently demonstrated to progress with increasing
AGel deposition [21]. The penetrance of the GSN
c.640G>A variant is 100%, but the manifestations of the
disease may vary signiﬁcantly between different patients
[5]. For the moment, patients can only be offered sympto-
matic treatment. However prominent amyloid elastosis in
dermal [22] and vascular tissues [23] may represent an
important target for future therapeutic strategies with anti-
amyloidogenic molecules, such as, e.g., AGel-speciﬁc
nanobodies [24–26].
All the Finnish patients examined so far carry the same
GSN c.640G>A variant. It is not known whether this is due
to a mutational hot spot in the gelsolin gene, which has been
the prevailing hypothesis concerning the gene variants in
different ethnic groups [27, 28], or due to a common
ancestor. Dr. Meretoja, a Finnish ophthalmologist who ﬁrst
described the disease in 1969 [1], suggested that all the
Finnish patients with this amyloidosis originate from one
common ancestor who lived over 600 years ago [3]. This
hypothesis has been later strengthened by the demonstration
of a homogeneous GSN c.640G>A variant [29] and the
uniformity of the disease associated haplotypes in 10 and
7 studied Finnish families [27, 28]. However, a more
comprehensive study on the subject has not been available.
We ﬁrst identiﬁed 79 Finnish AGel amyloidosis families
using methods of classical genealogy. After that we con-
ducted a haplotype analysis study. This included at least one
index patient from all available Finnish AGel amyloidosis
families. This study was conducted in order to ﬁnd out
whether the Finnish patients share a common haplotype,
indicative of a common ancestor.
Materials and methods
Genealogic study
A national registry for AGel amyloidosis patients in Fin-
land, FIN-GAR (The Finnish Gelsolin Amyloidosis Patient
Registry), was founded in 2013 [30]. In the process,
information on family history including affected individuals
and places of domiciles were collected by a questionnaire.
Majority (87% of the patients in the registry) were also
interviewed over telephone in order to get more detailed
data. In addition to this, some patients were able to give
written genealogy studies about their family. Everything
mentioned above was combined with already existing AGel
amyloidosis family data since the end of 1980s from pre-
vious studies of our research group. Access to the civil
registry and parish registers was also used in order to ﬁnd
information about the ancestors of the patients. Using
classical genealogy methods AGel amyloidosis families
were traced down as far as possible.
Subject selection for haplotype analysis
Because all family members of the same family affected
with AGel amyloidosis were assumed to share the same
disease haplotype, we invited one or two index patients
from each identiﬁed family to participate in the haplotype
analysis study. All the invited patients had characteristic
clinical manifestations of the disease and their diagnosis had
been made by an ophthalmologist or other physician. In 38
patients the diagnosis had also been conﬁrmed by a gene
test which veriﬁed the variant c.640G>A in the gelsolin
gene.
Only families including at least one member in FIN-
GAR patient register (72 out of 79 families) were enroled in
this study as they had given their consent to contact them
for research purposes. After giving the informed consent,
blood samples were collected from 71 index patients
representing 64 families. After the quality control, samples
from 68 index patients representing 62 families were left for
analysis. The subject selection process is presented in
Fig. 1.
Genotyping and haplotype analysis
Using the standard procedure of Wizard® Genomic DNA
Puriﬁcation kit the DNA was isolated from red blood cells.
First, red blood cells and their nuclei were lysed, followed
by protein precipitation. Finally, DNA was precipitated and
rehydrated. Concentrations and purity of DNA samples
were measured and samples were titrated to a predetermined
concentration (50 ng/μl).
Samples were then genotyped with CoreExome single-
nucleotide polymorphism (SNP) arrays and GenomeStudio
Fig. 1 Genealogic study and subject selection process
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v. 2011.1 software (Illumina, Inc., San Diego, CA, USA).
The SNP array contains different tag SNPs and detects these
markers from samples. Additional quality control for iden-
tity by descent (IBD, to remove duplicate samples) and sex
was performed using the PLINK software [31], which is a
computer program for SNP data handling. GSN c.640G>A
(rs121909715, GRCh37 chr9:g.124073097G>A) had been
previously tested as part of diagnostics in most cases. We
sequenced the gelsolin gene variant site in 33 patients by
Sanger sequencing using the following primers for gen-
erating the amplicon: 5ʹ-CACTGTGTTGCTGGAAAGCC-
3ʹ and 5ʹ-CGTGGATGTACCCAAGTCCC-3ʹ. The geno-
typing data are publically available at the ﬁgshare database
(dx.doi.org/10.6084/m9.ﬁgshare.5455495).
Patients’ haplotypes were analysed using the homo-
zygosity haplotype method [32]. Markers with a minor allele
frequency of at least 10% within the genotyped patient
samples and a genotyping rate of 95% or more were inclu-
ded in the analysis. The 10% minor allele frequency cut-off
was chosen to exclude markers with low informativeness.
The likelihood of a random ﬁnding at the GSN locus was
evaluated by two sampling methods. The ﬁrst evaluation
consisted of analysing 10,000 random permutations of the
SNP array marker labels and running an identical homo-
zygosity haplotype analysis for each such permutation of the
data. For the second method of evaluation, a sample of equal
size to the study cohort was repeatedly drawn from a larger
population-based cohort (Vantaa 85+, 10,000 random
samplings) and then the homozygosity haplotype analysis
was performed for each sample. The Vantaa 85+ study
sample [33] is a Finnish population-based cohort comprising
all subjects aged ⩾85 years from Vantaa, Finland as of 1
April 1991 (n= 601). Whole-genome sequencing has been
performed in a subsample, which was selected based on the
available DNA amount. Whole-genome sequencing was
performed in 309 samples with at least 4 µg good-quality
DNA left; of these, 300 yielded good-quality sequence data.
The sequencing was performed in Broad Institute using
PCR-free sample preparation with Illumina HiseqX chem-
istry, and we achieved a mean coverage of 27×. Only
markers present in the CoreExome SNP array were drawn
from the whole-genome sequence data for the random
sampling analysis.
The local Ethics Committee of the Helsinki University
Hospital has approved the study.
Results
Finnish AGel amyloidosis families
Altogether, 79 AGel amyloidosis families in Finland could
be traced down. After this, ancestors could no longer be
identiﬁed by classical genealogy methods. Family trees
included 2 to 106 patients.
The earliest suspected patients who could be identiﬁed
were born in the 1820s. A total of 29 (37%) families ori-
ginated from the Kymenlaakso area, which represents only
3% of the Finnish population. Lammi, a municipality
located in Southern Tavastia, represented a second geo-
graphical concentration with 10 (13%) families. Also, 9
(11%) families originated from areas southeast of Finland
that had been ceded to the Soviet Union after the Second
World War in 1944 (Fig. 2).
The identiﬁed 79 families included 707 patients, 235 of
whom were members of the FIN-GAR registry diagnosed
by a physician. The remaining patients were identiﬁed as
AGel amyloidosis patients based on reports of relatives and
earlier material collected by the research group. Therefore,
the method of diagnosis for them was unknown to us.
Fig. 2 Places of origin of the 62 AGel amyloidosis families. Larger
dots indicate a higher density of families with AGel amyloidosis
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Genotyping
A total of 71 blood samples from 64 families were available
for genotyping. These represent 81% of all identiﬁed 79
Finnish AGel amyloidosis families. All 71 genotyped
samples had a genotyping success rate of over 99%. Two
samples were removed from the analysis due to high degree
(100%) of IBD with each other and one sample was ruled
out because of gender mismatch. After quality control, 68
patient samples representing 62 families were available for
ﬁnal analysis. These families represent 78% of all currently
identiﬁed families. The baseline information of the patients
from these 62 families is given in Table 1.
Founder haplotype analysis
All patients had the GSN c.640G>A variant. We wanted to
test if these patients share a common founder haplotype at
the GSN locus. Using the homozygosity haplotype method
we identiﬁed a shared 17-SNP haplotype at the GSN locus
spanning 361 kb (GRCh37 coordinates 9:124003326–
124364349) (Fig. 3). By permutating the marker data we
estimated the likelihood of this ﬁnding by chance and found
it highly unlikely (zero occurrence in 10,000 simulated
permutations of the data). Moreover, in a genome-wide
analysis of the SNP array data, this was the largest haplo-
type shared by all patients (Fig. 4).
Next, we tested whether the GSN locus haplotype sharing
is a common feature of the Finnish population. We
empirically tested shared haplotypes in a population-based
sample of elderly Finns (Vantaa 85+, n= 300) using the
same marker set and same methodology. The same number
of samples (n= 68) was drawn randomly 10,000 times, and
we calculated how many times GSN locus appeared as a
shared haplotype. This analysis showed no shared haplo-
type at the GSN locus in any of the 10,000 random sam-
plings. Furthermore, we estimated the population frequency
of the 17-SNP haplotype in the full Vantaa 85+ data by
analysing subjects carrying at least one copy of the alleles
present in the haplotype. This procedure yielded a fre-
quency of 0.143, which is the theoretical maximum hap-
lotype frequency in the Vantaa 85+ sample, and it thus
appears highly unlikely that 68 subjects would share this
haplotype by chance. Taken together, these observations
support the concept that all of the patients share a common
ancestor.
Table 1 Baseline information on the 68 study subjects
Parameter N (%)
Gender distribution 22 Male (32%), 46 female (68%)
Mean age 62 Years
Characteristic
manifestations of the
diseasea
Ophthalmological symptoms: 67 (99%);
neurological symptoms: 56 (82%); skin
symptoms: 59 (87%)
aBoth or one of the most common two symptoms of each category
(corneal dystrophy gelsolin type (LCD2) and eye dryness, facial nerve
paresis and polyneuropathy, cutis laxa and drooping eyelids)
Fig. 3 Haplotype area in chromosome 9 that is shared between all subjects. The gelsolin (GSN) c.640G>A variant is marked in red. The 17 array-
genotyped SNPs that make up the haplotype are listed under visualizations of genes located in the area
Fig. 4 Genome-wide shared haplotype analysis. Shared haplotypes
were detected using the homozygosity haplotype method from SNP
array data. The highest peak corresponding to the largest detected
shared haplotype between all subjects encompasses the gelsolin gene
area and contains the gelsolin (GSN) c.640G>A variant
120 T. Mustonen et al.
Discussion
We present here the so far largest haplotype analysis in
AGel amyloidosis, which provides strong evidence indi-
cating that all the analysed 62 Finnish AGel amyloidosis
families have a common ancestor.
It has been previously suggested that there is a muta-
tional hot spot in this speciﬁc location c.640G [27, 28]. For
this reason it is possible that sporadic GSN c.640G>A
mutations have taken place independently in several per-
sons in Finland. This has been proposed to cause AGel
amyloidosis in different ethnic groups [27, 28]. However,
our data indicate that in Finland this is not the case. On the
contrary, the cases of AGel amyloidosis, reported in some
families in Japan [28] and the Netherlands [27], seem to
have arisen from sporadic de novo mutations and at least
two independent haplotypes have been reported in Japan
[34]. One family in the United States has been identiﬁed to
carry the same haplotype as the Finnish AGel amyloidosis
families [35]. However in most non-Finnish GSN
c.640G>A families worldwide haplotype analyses have not
been performed.
Among the 62 families, there were 61 who shared a very
large haplotype of 1290 kb with 55 markers (coordinates
9:123074244–124364349). Table 2 shows the markers of
both 361 kb and 1290 kb haplotypes. Thus, 98% of the
families have a larger haplotype and a single family reduced
the shared haplotype block to 361 kb. This indicates that a
recent recombination event has taken place in this family
between markers rs10818516 and rs10760160 (Table 2).
Most of the families presented here originate from the
Kymenlaakso region in South Eastern Finland. Additionally,
a large number of families originate from the municipality of
Lammi in Southern Tavastia, located in Southern Finland.
Areal concentration of the patients' places of birth is evident
also when regarding other diseases of the Finnish disease
heritage [4]. There are two background factors contributing
in the formation of the Finnish disease heritage. First,
national-level isolation inﬂuenced by geography, language,
culture and religion has kept the original gene pool homo-
geneous for generations. Second, the Finnish people have
typically stayed in their home region until the end of the
Second World War. This regional isolation together with
population expansion and genetic drift has enabled the
accumulation of different disease genes in certain loci [4].
It is not known whether the common ancestor of the
Finnish AGel amyloidosis patients originated from the
Kymenlaakso area or whether he/she moved there from
some unknown location. In this study this fact remains still
open for question, because so far we could not trace the
families further with classical genealogical methods in our
search of the common ancestor. Dr Meretoja suggested that
the common ancestor was a man called Matti of Oravalae
Table 2 Shared haplotype
Marker Coordinate
(GRCh37)
Genotype Allele frequency in
Finnish population
(gnomAD)
rs917873 chr9:123074244 A 0.85
rs2159994 chr9:123075135 G 0.86
rs1112863 chr9:123122187 G 0.56
rs1537282 chr9:123124504 C 0.6
rs7852998 chr9:123133385 C 0.59
rs7030519 chr9:123144243 G 0.23
rs914592 chr9:123170167 G 0.15
rs4837768 chr9:123170733 G 0.79
rs2297454 chr9:123171755 T 0.74
rs41296081 chr9:123239643 G 0.02
rs17343890 chr9:123349699 G 0.46
rs7861226 chr9:123351121 A 0.22
rs2416760 chr9:123374639 T 0.27
rs1324473 chr9:123404610 C 0.75
rs966396 chr9:123453281 C 0.75
rs2416799 chr9:123480866 T 0.75
rs2900177 chr9:123497645 T 0.75
rs7026635 chr9:123550027 A 0.7
rs10760117 chr9:123586737 G 0.58
rs881375 chr9:123652898 T 0.42
rs10435844 chr9:123668199 G 0.42
rs1014530 chr9:123685092 T 0.46
rs3761847 chr9:123690239 G 0.46
rs7039505 chr9:123705945 T 0.58
rs4836835 chr9:123757412 G 0.43
rs17611 chr9:123769200 C 0.5
rs2300932 chr9:123770436 A 0.36
rs34552775 chr9:123785738 T 0.02
rs7031128 chr9:123791936 C 0.28
rs7029523 chr9:123817613 T 0.28
rs10985140 chr9:123822837 G 0.42
rs10818503 chr9:123850770 G 0.37
rs10733651 chr9:123858194 G 0.37
rs10818504 chr9:123860689 C 0.53
rs10156413 chr9:123867782 T 0.35
rs2146838 chr9:123876305 G 0.45
rs4836840 chr9:123914592 T 0.37
rs10818516 chr9:123955756 G 0.53
rs10760160 chr9:124003326 C 0.55
rs10760165 chr9:124021254 T 0.58
rs3827677 chr9:124060879 C 0.75
rs306761 chr9:124075544 G 0.67
rs767769 chr9:124098336 A 0.48
rs17086 chr9:124125520 A 0.68
rs424829 chr9:124160616 C 0.74
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who might have lived in the fourteenth or ﬁfteenth century
in Lammi. He would have brought the disease to Valkeala
later on, located in the Northern Kymenlaakso [3]. Inter-
estingly, 9 families originated from the Karelia region,
indicating a possibility that the Finnish c.640G>A variant
could have originated from there.
Even though the study includes an index patient of the
large majority (78%) of the known Finnish AGel amyloi-
dosis families, its coverage is not 100%. Getting a complete
coverage is not feasible as there still might be some uni-
dentiﬁed families and not all of the patients want to take
part in studies.
This study represents the most comprehensive study on
the Finnish AGel amyloidosis haplotype so far and together
with the previous studies [27, 28] it indicates that most, if
not all, known Finnish AGel amyloidosis patients share a
common ancestor. In the future work on the classical gen-
ealogy concerning Finnish AGel amyloidosis patients will
be continued in order to ﬁnd out where the common
ancestor came from. Investigating the age of the GSN
c.640G>A variant would further clarify the history and the
origin of the disease. In the following haplotype studies it
would be interesting to examine further how widely this
haplotype has spread among non-Finnish AGel amyloidosis
families, and how much the disease is caused by sporadic
hot spot mutations worldwide.
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